{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:15:29Z","timestamp":1791206129312,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":730,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Severe liver disease caused by chronic hepatitis C virus is the major indication for liver transplantation. Despite recent advances in antiviral therapy, drug toxicity and unwanted side effects render effective treatment in liver-transplanted patients a challenging task. Virus-specific therapeutic antibodies are generally safe and well-tolerated, but their potential in preventing and treating hepatitis C virus (HCV) infection has not yet been realized due to a variety of issues, not least high production costs and virus variability. Heavy-chain antibodies or nanobodies, produced by camelids, represent an exciting antiviral approach; they can target novel highly conserved epitopes that are inaccessible to normal antibodies, and they are also easy to manipulate and produce. We isolated four distinct nanobodies from a phage-display library generated from an alpaca immunized with HCV E2 glycoprotein. One of them, nanobody D03, recognized a novel epitope overlapping with the epitopes of several broadly neutralizing human monoclonal antibodies. Its crystal structure revealed a long complementarity determining region (CD3) folding over part of the framework that, in conventional antibodies, forms the interface between heavy and light chain. D03 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes and authentic cell culture\u2013derived particles by interfering with the E2-CD81 interaction. In contrast to some of the most broadly neutralizing human anti-E2 monoclonal antibodies, D03 efficiently inhibited HCV cell-to-cell transmission.\n                      <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                      : This is the first description of a potent and broadly neutralizing HCV-specific nanobody representing a significant advance that will lead to future development of novel entry inhibitors for the treatment and prevention of HCV infection and help our understanding of HCV cell-to-cell transmission. (Hepatology 2013;53:932\u2013939)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26430","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T11:06:20Z","timestamp":1364468780000},"page":"932-939","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":79,"title":["An Alpaca Nanobody Inhibits Hepatitis C Virus Entry And Cell-To-Cell Transmission"],"prefix":"10.1097","volume":"58","author":[{"given":"Alexander W.","family":"Tarr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lafaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Damier-Piolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Urbanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Meola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Jestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix A.","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20241201","doi-asserted-by":"crossref","first-page":"637659","DOI":"10.1016\/j.cld.2008.03.010","article-title":"Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted.","volume":"12","author":"Verna","year":"2008","journal-title":"Clin Liver Dis"},{"key":"R2-14-20241201","doi-asserted-by":"crossref","first-page":"962973","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"R3-14-20241201","doi-asserted-by":"crossref","first-page":"667678","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and Tcell responses during chronic infection in vivo.","volume":"132","author":"von Hahn","year":"2007","journal-title":"Gastroenterology"},{"key":"R4-14-20241201","doi-asserted-by":"crossref","first-page":"12921303","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection.","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-14-20241201","doi-asserted-by":"crossref","first-page":"14291436","DOI":"10.1002\/hep.20934","article-title":"Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee.","volume":"42","author":"Youn","year":"2005","journal-title":"Hepatology"},{"key":"R8-14-20241201","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.","volume":"14","author":"Law","year":"2008","journal-title":"Nature Med"},{"key":"R9-14-20241201","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog"},{"key":"R11-14-20241201","doi-asserted-by":"crossref","first-page":"23772386","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"key":"R12-14-20241201","doi-asserted-by":"crossref","first-page":"60256030","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virusneutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C.","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R13-14-20241201","doi-asserted-by":"crossref","first-page":"15311542","DOI":"10.1002\/hep.23862","article-title":"Association of antiE1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus.","volume":"52","author":"Ndongo","year":"2010","journal-title":"Hepatology"},{"key":"R14-14-20241201","doi-asserted-by":"crossref","first-page":"596605","DOI":"10.1128\/JVI.01592-10","article-title":"Neutralizing antibodyresistant hepatitis C virus celltocell transmission.","volume":"85","author":"Brimacombe","year":"2011","journal-title":"J Virol"},{"key":"R15-14-20241201","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/hep.21959","article-title":"Hepatitis C virus cellcell transmission in hepatoma cells in the presence of neutralizing antibodies.","volume":"47","author":"Timpe","year":"2008","journal-title":"Hepatology"},{"key":"R16-14-20241201","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus celltocell transmission in hepatoma cells.","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J Gen Virol"},{"key":"R17-14-20241201","first-page":"446448","article-title":"Naturally occurring antibodies devoid of light chains.","volume":"363","author":"HamersCasterman","year":"1993","journal-title":"Nature"},{"key":"R18-14-20241201","doi-asserted-by":"crossref","first-page":"695704","DOI":"10.1016\/j.molimm.2008.09.008","article-title":"Singledomain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abetainduced neurotoxicity and inhibit fibril formation.","volume":"46","author":"Lafaye","year":"2009","journal-title":"Mol Immunol"},{"key":"R19-14-20241201","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid singledomain antibody fragments.","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"key":"R20-14-20241201","doi-asserted-by":"crossref","first-page":"389407","DOI":"10.1016\/j.antiviral.2011.09.002","article-title":"Nanobodies: new ammunition to battle viruses.","volume":"92","author":"Vanlandschoot","year":"2011","journal-title":"Antiviral Research"},{"key":"R21-14-20241201","doi-asserted-by":"crossref","first-page":"257264","DOI":"10.1016\/j.antiviral.2010.05.012","article-title":"In vitro antiviral activity of single domain antibody fragments against poliovirus.","volume":"87","author":"Thys","year":"2010","journal-title":"Antiviral Res"},{"key":"R23-14-20241201","doi-asserted-by":"crossref","first-page":"42464257","DOI":"10.1128\/JVI.01332-10","article-title":"Hepatitis C patientderived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.","volume":"85","author":"Tarr","year":"2011","journal-title":"J Virol"},{"key":"R24-14-20241201","doi-asserted-by":"crossref","first-page":"1626916274","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-14-20241201","doi-asserted-by":"crossref","first-page":"11211131","DOI":"10.1016\/S0161-5890(97)00146-6","article-title":"Comparison of llama VH sequences from conventional and heavy chain antibodies.","volume":"34","author":"Vu","year":"1997","journal-title":"Mol Immunol"},{"key":"R26-14-20241201","doi-asserted-by":"crossref","first-page":"921930","DOI":"10.1093\/emboj\/19.5.921","article-title":"Camel heavychain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigenbinding repertoire.","volume":"19","author":"Nguyen","year":"2000","journal-title":"EMBO J"},{"key":"R27-14-20241201","doi-asserted-by":"crossref","first-page":"16651669","DOI":"10.1126\/science.276.5319.1665","article-title":"Structural insights into the evolution of an antibody combining site.","volume":"276","author":"Wedemayer","year":"1997","journal-title":"Science"},{"key":"R28-14-20241201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1099\/vir.0.035956-0","article-title":"The role of neutralizing antibodies in hepatitis C virus infection.","volume":"93","author":"Edwards","year":"2012","journal-title":"J Gen Virol"},{"key":"R29-14-20241201","doi-asserted-by":"crossref","first-page":"19471955","DOI":"10.1002\/hep.24610","article-title":"The green tea polyphenol, epigallocatechin3gallate, inhibits hepatitis C virus entry.","volume":"54","author":"Ciesek","year":"2011","journal-title":"Hepatology"},{"key":"R30-14-20241201","doi-asserted-by":"crossref","first-page":"e1001086","DOI":"10.1371\/journal.ppat.1001086","article-title":"A novel small molecule inhibitor of hepatitis C virus entry.","volume":"6","author":"Baldick","year":"2010","journal-title":"PLoS Pathog"},{"key":"R31-14-20241201","doi-asserted-by":"crossref","first-page":"169174","DOI":"10.1093\/protein\/gzp088","article-title":"Efficient method for production of high yields of Fab fragments in Drosophila S2 cells.","volume":"23","author":"Backovic","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"R32-14-20241201","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1093\/protein\/gzr058","article-title":"Highlevel secretion of recombinant monomeric murine and human singlechain Fv antibodies from Drosophila S2 cells.","volume":"25","author":"Gilmartin","year":"2012","journal-title":"Protein Eng Des Sel"},{"key":"R33-14-20241201","first-page":"680687","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation.","volume":"35","author":"GarciaRetortillo","year":"2002","journal-title":"Hepatology"},{"key":"R34-14-20241201","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"R35-14-20241201","doi-asserted-by":"crossref","first-page":"e1000762","DOI":"10.1371\/journal.ppat.1000762","article-title":"The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.","volume":"6","author":"Krey","year":"2010","journal-title":"PLoS Pathog"},{"key":"R36-14-20241201","doi-asserted-by":"crossref","first-page":"94999504","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.","volume":"109","author":"Kong","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R37-14-20241201","doi-asserted-by":"crossref","first-page":"592601","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"R38-14-20241201","doi-asserted-by":"crossref","first-page":"1045110463","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81binding region that does not tolerate neutralization escape mutations.","volume":"85","author":"Keck","year":"2011","journal-title":"J Virol"},{"key":"R39-14-20241201","doi-asserted-by":"crossref","first-page":"19091932","DOI":"10.3390\/v3101909","article-title":"The hepatitis C virus glycan shield and evasion of the humoral immune response.","volume":"3","author":"Helle","year":"2011","journal-title":"Viruses"},{"key":"R40-14-20241201","doi-asserted-by":"crossref","first-page":"815826","DOI":"10.1038\/nrmicro1972","article-title":"Avoiding the void: celltocell spread of human viruses.","volume":"6","author":"Sattentau","year":"2008","journal-title":"Nature Rev Microbiol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26430","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201309000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:09:35Z","timestamp":1733044175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201309000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26430","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}